insights_auto
Pse është ulur BT3 6,00%?
Zhytu më thellëchevron_right
BT3:FRA
Lineage Cell Therapeutics Inc
0,83 €
arrow_downward
-6,00%(-0,053) 1D
13 tet, 8:01:24 p.d., GMT+2 · EUR
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për BT3...
Hap
0,83 €
I lartë
0,83 €
I ulët
0,83 €
Kapitalizimi i tregut
231,42 mln
Vëllimi mesatar
37,00
Vëllimi
0,00
Maksimumi 52-javor
1,69 €
Minimumi 52-javor
0,78 €
Numri i punonjësve
75
Hap
0,83 €
I lartë
0,83 €
I ulët
0,83 €
Kapitalizimi i tregut
231,42 mln
Vëllimi mesatar
37,00
Vëllimi
0,00
Maksimumi 52-javor
1,69 €
Minimumi 52-javor
0,78 €
Numri i punonjësve
75
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
Benzinga
·
1 ditë më parë
Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Call
Profili
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
Rreth Lineage Cell Therapeutics Inc